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Among food-related toxic outbreaks that
have occurred in the world, the Spanish toxic
oil syndrome (TOS) emerges as a significant
disaster because of the degree of severity and
the huge population involved (1,2). In May
1981 the TOS appeared in Madrid and
northwestern areas of Spain as a unique dis-
ease caused by the ingestion of adulterated
rapeseed oil denatured with aniline (3–7).
More than 20,000 people were affected; of
these, over 11,000 required hospitalization
and over 300 deaths were registered in the
first 2 years (1,8). Although the majority of
patients recovered after a long period,
30–40% continue to suffer mild symptoms
or severe sequelae (9–12). TOS was charac-
terized as a multisystemic disease with three
consecutive phases. In the acute phase (1–2
months), patients presented fever, rash,
eosinophilia, pulmonary edema, and myalgia.
Many patients (59%) progressed to an inter-
mediate phase with pulmonary hypertension,
thromboembolism, persistent myalgia and
eosinophilia, skin edema, alopecia, and sicca
syndrome. The clinical signs of the chronic
phase were principally pulmonary hyperten-
sion, scleroderma, peripheral neuropathy,
and liver disease. A summary of clinical and
epidemiological findings has been compiled
in recent reviews (9–11,13,14). 
Rapeseed oil, denatured with 2% aniline,
was imported for industrial purposes and ille-
gally refined and delivered for human con-
sumption. A strong association of TOS with
ingestion of this oil was proven (3–5,15);
thus, the syndrome was caused by toxicants
in the oil (1,6,7,13,15,16). Despite the ana-
lytical efforts seeking toxic substances in these
oils, only aniline derivatives such as fatty acid
anilides (1,3,17,18) and fatty acid esters of 3-
phenylamino-1,2-propanediol (PAP esters)
(19–21) have been identified in toxic oil
batches. The content of oleanilides and PAP
esters in the oil has been strongly associated
with the morbidity caused by these oil
batches in the corresponding households
(16,22,23). In particular, the di-oleyl-PAP
ester (OOPAP) is considered the putative
toxic substance generated during the refining
process (23,24); however, its toxicity mecha-
nism in biological systems has not yet been
fully clarified. Extensive experiments in
diverse animal species fed with toxic oil or
administered aniline derivatives have failed to
reproduce the full spectrum of the disease
(1,25,26). This may suggest a species-specific
toxicity for humans; in this respect, species
differences in aniline toxicity have been rec-
ognized for decades and attributed to metab-
olism differences (27–30).
The disease tended to cluster in families,
and the exposure factor was shown to be
closely related to household life (4–7).
Nevertheless, members of the same family
seemed to differ in their risk of becoming ill
(4,5), which suggested consumption of dif-
ferent amounts of the oil (a dose factor)
and/or a susceptibility trait. With respect to
the latter, an immunological mechanism was
initially suggested as a toxicity target and was
extensively investigated (31–33) because the
disease resembled an allergic–toxic syndrome
in the acute phase and an autoimmune con-
dition in the chronic phase. However, with
regard to a dose factor in toxicity, the
patients’ detoxification mechanisms have not
yet been investigated. The real toxic dose
ingested by patients before the oil was offi-
cially recalled was unknown. Epidemiological
studies on dietary habits in 1981 failed to
conclusively establish a correlation between
oil consumption and severity of the disease
(4,5). However, these studies did not pro-
vide analytical data on aniline-derivative
content in the household-distributed oil
batches; to date, it is known that oleylanilide
and OOPAP content varied several folds in
oil batches (18,22–24). This would suggest
that some families might have suffered a poi-
soning dose due to a high toxicant(s) content
in their edible oil batch, whereas other fami-
lies may have reflected a susceptible trait
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Articles
In 1981, the Spanish toxic oil syndrome (TOS) affected more than 20,000 people, and over 300
deaths were registered. Assessment of genetic polymorphisms on xenobiotic metabolism would
indicate the potential metabolic capacity of the victims at the time of the disaster. Thus, impaired
metabolic pathways may have contributed to the clearance of the toxicant(s) leading to a low
detoxification or accumulation of toxic metabolites contributing to the disease. We conducted a
matched case–control study using 72 cases (54 females, 18 males) registered in the Official
Census of Affected Patients maintained by the Spanish government. Controls were nonaffected
siblings (n =72) living in the same household in 1981 and nonaffected nonrelatives (n = 70) living
in the neighborhood at that time, with no ties to TOS. Genotype analyses were performed to
assess the metabolic capacity of phase I [cytochrome P450 1A1 (CYP1A1), CYP2D6] and phase
II [arylamine N-acetyltransferase-2 (NAT2), GSTM1 (glutathione S-transferase M1) and
GSTT1] enzyme polymorphisms. The degree of association of the five metabolic pathways was
estimated by calculating their odds ratios (ORs) using conditional logistic regression analysis. In
the final model, cases compared with siblings (72 pairs) showed no differences either in CYP2D6
or CYP1A1 polymorphisms, or in conjugation enzyme polymorphisms, whereas cases compared
with the unrelated controls (70 pairs) showed an increase in NAT2 defective alleles [OR = 6.96,
95% confidence interval (CI), 1.46–33.20] adjusted by age and sex. Glutathione transferase
genetic polymorphisms (GSTM1, GSTT1) showed no association with cases compared with their
siblings or unrelated controls. These findings suggest a possible role of impaired acetylation medi-
ating susceptibility in TOS. Key words: CYP1A1, CYP2D6, enzyme genetic polymorphisms,
GSTM1, GSTT1, molecular epidemiology, NAT2, Spanish toxic oil syndrome, xenobiotic
metabolism. Environ Health Perspect 109:369–375 (2001). [Online 16 March 2001]
http://ehpnet1.niehs.nih.gov/docs/2001/109p369-375ladona/abstract.html
even with low toxicant content in their oil
batch (Figure 1). 
TOS, as the result of a toxic chemical
ingestion, would invite investigation on the
subject’s capacity to biotransform and elimi-
nate the toxic agent(s). Thus, differences in
xenobiotic metabolism and inherited genes
among exposed subjects may have con-
tributed to the overall clearance and elimina-
tion of the toxicant(s), resulting in an
accumulation of toxic metabolites, or a low
detoxification, contributing to the disease. In
this context, polymorphic genes that encode
drug-metabolizing enzymes are attractive can-
didates for unraveling mechanisms of genetic
susceptibility in adverse drug reactions or in
xenobiotic exposure toxicity (34,35). Phase I
enzymes may metabolically activate xenobi-
otics and procarcinogens, yielding toxic or
carcinogenic electrophiles, respectively; phase
II enzymes may be implicated in detoxifying
such products. In this study we attempt to
identify host-metabolism differences (i.e.,
genetic susceptibility factors) that may have
played a role in the pathogenesis of TOS. In
other words, our goal was to determine
whether the TOS population inherited a par-
ticular genetic profile with regard to xenobi-
otic enzyme metabolism, which would imply
impaired or increased metabolic capacity
toward chemical exposure.
Methods
Population selection and study variables. The
study was designed as a matched case–control
study with two different controls—nonaf-
fected siblings and unrelated nonaffected
subjects—hereinafter referred to as siblings
and friends, respectively. Cases were recruited
from five areas where the Associations of
TOS-Affected Patients cooperated. 
Inclusion criteria for cases were the same
as those used in other TOS studies (16); cases
included patients registered in the TOS
Official Census who underwent an acute
and/or chronic phase of the disease. The
acute phase is defined as an alveolo-intersti-
tial lung infiltration and/or pleural effusion
with absolute eosinophilia (> 500 cells/mm3).
The chronic phase is defined as myalgia and
eosinophilia, and/or scleroderma, neuropa-
thy, pulmonary hypertension or hepatopathy
clearly attributed to TOS disease. Siblings
were selected from among brothers or sisters
who lived with the case and shared the same
meals with him/her when the epidemic
started in 1981 and when the case became ill.
After we selected the case and his/her sibling,
the case himself/herself chose the unrelated
control from among his/her friends, provided
the friend had lived in the same locality in
1981 when the epidemic broke out and had
had no affected family members. Exclusion
criteria included pregnancy, age > 65 years,
mental disorders, and reluctance to collabo-
rate in the study. Neither siblings nor friends
had to present symptoms or signs of the ill-
ness. We gave a questionnaire and an
informed consent form to each selected per-
son. All subjects recruited for this study were
informed of the aims of the investigation in
detail and asked to give their written consent
to participate. The study was approved by
the Ethics Committee of Hospital 12 de
Octubre (Madrid).
Recruited subjects were coded by random
numbers; blood samples were collected, cor-
respondingly labeled, and frozen at –80°C
until analysis. All analytical determinations
and questionnaire data management were
carried out by personnel unaware of the iden-
tity or biochemical data of the patient. Two
variables described case or control status and
its specific matching group. Other variables
were geographical residence in 1981, age, sex,
and health status. Metabolic variables to be
studied were genetic polymorphisms in xeno-
biotic metabolism phase I [cytochrome P450
1A1 (CYP1A1), CYP2D6] and phase II [ary-
lamine N-acetyltransferase-2 (NAT2), glu-
tathione S-transferase M1 (GSTM1) and
GSTT1] enzymes. 
Genotyping analysis. We analyzed all of
the samples in blind conditions with regard to
case–control status. Genotype analyses were
made on genomic DNA isolated from blood
collected in EDTA tubes and frozen at –80°C
until assayed. Genomic DNA was extracted
from the leukocyte pellet by standard phenol
extraction followed by isopropanol precipita-
tion and was stored at 4°C in TE buffer (10
mM Tris-HCl, pH 8.0, 1 mM EDTA).
Genotypes were assessed by polymerase chain
reaction (PCR) allele-specific amplification of
functional genes. Further nested PCR or
enzyme restriction endonuclease (PCR-
RFLP) analyses permitted assessment of spe-
cific point mutations in intron–exon
sequences known to impair enzyme activity.
We determined the CYP2D6 gene locus by
genomic RFLPs using a non-radioactive
Southern blot technique and following the
manufacture’s instructions (DIG DNA label-
ing and DIG luminescent detection kits;
Boehringer Mannheim, Germany). We
established specificity of the PCR techniques
and confirmed PCR products by sequencing.
Homozygous and heterozygous control sam-
ples were subsequently included in all reac-
tions. All samples with mutations and 10%
of samples with wild type/wild type (wt/wt)
haplotype were confirmed. We used two
molecular methods to assess mutations in
NAT2 and CYP2D6 polymorphisms,
thereby confirming results. Therefore, these
quality control measures fully validated the
participants’ genotypes.
Methods to determine CYP2D6 point
mutations (A2637 deletion, G1934A) were
established as described elsewhere (36,37).
Gene deletions and duplications were identi-
fied by XbaI/EcoRI RFLPs (38) using a
cDNA probe provided by U.A. Meyer
(Biocentre, Basel, Switzerland). Combined
PCR and RFLPs analyses defined CYP2D6
genotypes according to established nomen-
clature (39). These genotypes are believed to
account for 95% of the known CYP2D6
polymorphism (40–42). With regard to
CYP1A1 polymorphisms, two MspI sites
reported in ethnic differences were detected
by PCR-RFLPs described at the 3´ gene-
flanking region, and a point mutation in
exon 7 at codon 462 (A4889G) producing an
amino acid exchange (isoleucine-valine) was
also determined (43–45). We used the
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Figure 1. Factors that contribute to TOS differential morbidity observed in households: toxic dose and
metabolism.
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nomenclature of Taioli et al. (45) to name the
CYP1A1 genotypes: C, wild-type allele; M,
the allele with the MspI site at the 3´-flanking
region (T6235C); D, the allele with MspI site
plus valine mutation; and A, the allele with
the MspI site at 5315 nucleotide (T5315C).
Gene deletions causing impairment of
GSTM1 (46) and GSTT1 (47) were analyzed
by well-described allele-specific PCR methods
(47,48). These methods permitted identifica-
tion of the homozygous deleted gene, the so-
called null allele (GSTM1– or GSTT1–),
from the heterozygous and homozygous wild
type haplotype, the wt allele (GSTM1+ or
GSTT1+). Finally, we assessed the NAT2
genetic polymorphism to identify m1 (T341C,
C481T), m2 (G590A), and m3 (G857A) point
mutations in the coding region (49). These
mutations account for 90–95% of the
enzyme’s capacity variability described for
NAT2 polymorphism (41,50,51).
All chemical reagents, of molecular and
analytical grade, were purchased from Sigma
Chemical (St. Louis, MO, USA) and Merck
(Darmstadt, Germany). We obtained syn-
thetic primers and 2´-deoxynucleosides-5´-
triphosphate from Pharmacia Biotech
(Uppsala, Sweden), restriction enzymes from
Gibco-BRL (Gaithersburg, MD, USA), and
Taq polymerase from Perkin Elmer
(Norwalk, CT, USA).
Statistical analysis. Each genetic variable
was tested separately for its distribution in
each group (cases, siblings, and friends) and
given as allele frequencies. 
We defined three metabolic categories on
the basis of their functional and nonfunc-
tional derived haplotypes: wt/wt, wt/mutant
(wt/m), and m/m. We then designed dummy
variables to evaluate the independence of each
genetic category. The absence of mutations
(wt/wt) was considered the metabolic basal
risk, which was compared with the heterozy-
gous (wt/m) or homozygous (m/m) mutations.
We used univariate conditional logistic regres-
sion to measure the relative risk of cases versus
siblings and cases versus friends. Data are
shown as odd ratios (ORs) with 95% confi-
dence intervals (CIs).
We performed multivariate analysis by
applying multivariate conditional logistic
regression following a backward strategy,
including all metabolic pathways of phase I
and phase II to test their interactions and
adjusting by age and sex. Variables were
retained if they achieved statistical significance
(p ≤ 0.05) or if, in order to control con-
founders, their absence changed the remain-
ing estimated coefficients by at least 15%. To
give adjusted estimators, sex and age were also
retained despite their significance. We used
the change in the –2 log likelihood to com-
pare different models. Analyses were per-
formed with the Epidemiological Graphics
Estimation and Testing software (EGRET,
analysis module verison 0.26.6, EPIXACT
version 0.03 1985–1991; Cytel, Cambridge,
MA, USA). 
Results
We collected and analyzed samples from 236
subjects (80 cases, 80 siblings, and 76
friends) with their corresponding question-
naires. We excluded 21 subjects from the
statistical analyses. Of these, 7 cases were
excluded because 2 were not officially regis-
tered as cases and 5 did not fulfill inclusion
criteria; their corresponding 7 siblings were
also excluded. In addition, 1 sibling was
excluded because there was no age match
(born after the outbreak). In the friends
group, 4 were excluded because they had no
case for comparison and 2 were excluded
because they did not live in same geographi-
cal area as their case at the time of the disas-
ter. As a result, we identified 215 subjects as
73 cases, 72 siblings, and 70 friends, thus
yielding 72 and 70 matched-pair series for
comparison. Women were overrepresented
among cases (75% vs. 54% in siblings and
48.6% in friends). On average, cases were
younger than their friends but not younger
than their siblings (median: 27 years for
cases, 26.5 years for siblings, and 29 years for
friends). The clinical symptom profile of the
included cases at the time of the outbreak is
shown in Table 1.
Descriptive results of phase I metabolic
pathways, CYP1A1 and CYP2D6 enzyme
genetic polymorphisms are shown in Table
2 and Figure 2. Allele frequencies of
CYP1A1 polymorphism in the seventh exon
(isoleucine/valine amino acid exchange) and
at the 3´ gene-flanking region (MspI restric-
tion sites) are listed in Table 2. Cases pre-
sented a higher frequency of mutated alleles
with MspI and valine point mutations (M, A,
and D alleles, respectively); however, they did
not reach statistical significance compared to
controls. Mutation at the seventh exon was
always linked to the presence of the 3´ MspI
site (T6235 C), i.e., the D allele. For two sub-
jects in the friends group, the MspI restriction
site reported for African Americans (44) was
confirmed by sequencing analyses. The func-
tional metabolic categories established
included the haplotype combinations of wt
(C allele) and the mutant alleles (M or D)
(Figure 2A) and reflected a higher proportion
of C/D haplotype in the case group compared
to friends (OR = 2.8; 95% CI, 0.9–9.0). 
CYP2D6 metabolic capacity was assessed
by determining point mutations and the
genomic locus, as described in “Methods.”
Genotype categories were defined according
to established nomenclature (39). XbaI and
EcoRI restriction endonucleases permitted
detection of deletions and clear differentia-
tion of 44 and 42 kb fragments. No subject
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Table 1. Characteristics of TOS cases (n = 72).a
Clinical features in 1981 n %
Eosinophilia 66 91.7
Pulmonary disease 64 88.9
Myalgia 66 91.6
Neuropathy 23 31.9
Scleroderma 20 27.8
Hepatopathy 6 8.3
Pulmonary hypertension 4 5.6
Eosinophilia + myalgia 60 83.3
Eosinophilia + pulmonary + myalgia 53 73.6
Eosinophilia + myalgia + neuropathy 22 30.6
aWe used the same inclusion criteria for cases as used
previously (16).
Table 2. Phase I metabolism: allele frequencies of
CYP1A1 and CYP2D6 genetic polymorphisms. 
Cases Siblings Friends
Allelle1 (n = 73) (n = 72) (n = 70)
CYP1A1
C 0.86 0.89 0.90
A – 0.01 0.01
M 0.06 0.05 0.06
D 0.08 0.05 0.03
wt 0.86 0.89 0.90
m 0.14 0.11 0.10
CYP2D6
1* 0.66 0.72 0.73
2 × 2* 0.06 0.05 0.03
3* 0.02 0.03 –
4* 0.25 0.20 0.21
5* 0.01 – 0.03
wt 0.72 0.77 0.76
m 0.28 0.23 0.24
Haplotypes (2 × 2* mutation or deletion) were categorized
wt/wt as having 2 functional genes, i.e,. CYP2D6 2 × 2*.
Nomenclature is as reported for CYP1A1 (46) and CYP2D6
(39).
100
90
80
70
60
50
40
30
20
10
0
80
70
60
50
40
30
20
10
0
C/C C/M + C/A C/D wt/wt wt/m m/m
Cases
Siblings
Friends
A B
Pe
rc
en
t o
f p
op
ul
at
io
n
Pe
rc
en
t o
f p
op
ul
at
io
n
Figure 2. Phase I metabolism of CYP1A1 and CYP2D6 genetic polymorphisms. (A) CYP1A1 functional haplo-
type categories given as a percentage. (B) CYP2D6 functional haplotype categories given as percentages.
wt indicates a functional allele, and m indicates a nonfunctional allele. 
presented homozygous gene deletions (i.e.,
the 11.5 kb fragment). The XbaI 16+9 frag-
ments were linked to a G1934A mutation
and accounted for 3% in the entire sample
collection. The XbaI-derived and EcoRI-con-
firmed 44 kb fragment was also linked to the
presence of the splicing defect G1934A, as
determined by PCR analyses. In contrast, the
duplication fragment i.e., the 42 kb allele was
always associated with wt PCR alleles and
was clearly differentiated from 44 kb frag-
ments by EcoRI restriction endonuclease. A
novel XbaI RFLP of 33+9 kb was found in
three subjects as a heterozygous 29 kb haplo-
type with an EcoRI pattern indistinguishable
from the 42 kb allele. Thus, this may suggest
that a new XbaI mutation had appeared in a
42 kb allele, giving the 9 kb fragment (52).
This 33+9 RFLP fragment was also linked to
mutation G1934A and considered as a
CYP2D6*4 nonfunctional allele. Prevalence
of CYP2D6 defective alleles among cases was
higher compared to their relative controls
(Figure 2B), which could imply that an
impaired metabolism may have operated in
some patients. 
Genotype distributions of conjugation
pathways (glutathione S-transferase and ary-
lamine-N-acetyl-transferase major detoxifica-
tion pathways) are shown in Table 3 and
Figure 3. NAT2 point mutations (m1:
C341,T481; m2: A590; m3: A857) causing
enzyme-impaired function by posttranscrip-
tional mechanisms were distributed in eight
different haplotype combinations with the
wt functional allele. Allele frequencies are
listed in Table 3. A higher prevalence of
defective alleles, in particular the m2 and m3
allele frequencies, was observed in cases com-
pared with friends. The sibling group pre-
sented a higher prevalence of the m1 allele
than the friend controls. The metabolic cate-
gories derived from haplotype combinations
reflected a lower proportion of functional
haplotypes (wt/wt) among cases compared
with friends (Figure 3A), thus suggesting
that some impaired NAT2 function may be
associated with TOS cases.
Gene deletions in GSTM1 and GSTT1
isoenzymes were determined by PCR (Table
3). Gene prevalence of homozygous null
haplotype in GSTM1 and GSTT1 was
almost equally distributed among groups
(Figure 3B,3C) and was also equally distrib-
uted after age and sex stratification. In consid-
ering genetic combinations of both enzymes,
we observed two subgroups of cases: patients
with a null haplotype in both GST enzymes
(18% with GSTM1–/GSTT1–) or patients
with a wt allele for both enzymes (41% with
GSTM1+/GSTT1+). In the present study, it
is impossible to establish whether this obser-
vation indicates subpopulations with vari-
ability in their clinical presentations,
characteristics, or phenotype.
We performed statistical analyses to test
the hypothesis that case subjects may present
a different metabolic profile from their con-
trols, which would indicate that the enzyme
metabolic capacity of case subjects was associ-
ated with and challenged by TOS xenobiotic
intoxication. Instead of comparing the allele
frequencies observed, we chose to study
genetic functional capacity because enzyme
activity is determined by the presence and/or
absence of mutations. Moreover, enzymatic
capacity of haplotypes with one or both func-
tional alleles would be subsequently chal-
lenged if doses were accumulative. Thus,
homozygous mutant haplotypes would be
the first at risk, and heterozygous and
homozygous wild types would consecutively
be involved because increasing doses would
exhaust the subject’s metabolic capacity.
Using the three genetic categories (wt/wt,
wt/m, and m/m) as dummy variables, we eval-
uated independently the risk in CYP1A1,
CYP2D6, NAT2, GSTT1, and GSTM1
enzymatic pathways. Table 4 shows the per-
centage distribution of all metabolic variables
considered among the two matching series
(cases vs. siblings, cases vs. controls). As
stated above, we contrasted wt/wt haplotypes
with the sum of heterozygous and homozy-
gous mutated haplotypes.
The degree of association for each vari-
able was assessed by conditional logistic
regression analysis and the odds ratio of each
was calculated. The estimated odd ratios in
the final conditional logistic regression
model adjusted by all metabolic variables,
sex, and age, as described in “Methods,” are
shown in Table 5. In the final models, we
excluded enzyme polymorphisms that failed
to add any information to the model. We
observed no differences in phase I metabo-
lism among cases compared with their corre-
sponding siblings or in the conjugation
enzymes tested. In contrast, comparison
with friends showed a distinct metabolic
profile in cases with a high prevalence of
defective NAT2 alleles (wt/m + m/m) (OR =
6.96; 95% CI, 1.4–33.2).
Discussion
It is difficult and challenging to assess meta-
bolic profiles that occurred 19 years ago at the
time of the massive intoxication. Epigenetic
modulation of genetic load expression in sur-
viving patients caused by TOS disease or
physiological and environmental factors
should have operated in each subjects’ present
metabolic capacity (present phenotype); how-
ever, each subject’s pharmacogenetic profile
would have been the same. Therefore, phar-
macogenetic determinations made now may
yield interesting information for explaining
the subjects’ interindividual differences in sus-
ceptibility to past toxicant exposure and
would provide better understanding of the
detoxification/toxification mechanisms
involved in massive toxic outbreaks. After
years of research on TOS, this study is the
first to point out a specific metabolic profile
in patients, that is, an increase in NAT2
defective alleles. Thus, patients with NAT2
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Figure 3. Phase II metabolism: conjugation pathways of NAT2 and GST genetic polymorphisms. Functional categories of (A) NAT2, (B) GSTM1, and (C) GSTT1
expressed as a percentage in the population. 
Table 3. Phase II metabolism: allele frequencies
of NAT2 and GST genetic polymorphisms. 
Cases Siblings Friends
Allelle1 (n = 73) (n = 72) (n = 70)
NAT2
wt 0.27 0.30 0.38
m1 0.38 0.43 0.37
m2 0.32 0.25 0.23
m3 0.03 0.02 0.02
m 0.73 0.70 0.62
GSTM1
GSTM1+ 0.52 0.54 0.46
GSTM1– 0.48 0.46 0.54
GSTT1
GSTT1+ 0.71 0.74 0.69
GSTT1– 0.29 0.26 0.31
Nomenclature is as reported for NAT2 (49), GSTM1 (48),
and GSTT1 (47).
homozygous mutant haplotypes would be
the first at risk; heterozygous and homozy-
gous wild types consecutively would be
involved because accumulative doses would
exhaust each subject’s metabolic capacity.
Some factors should be highlighted in con-
nection with the TOS problem: a) a large
proportion of the population was exposed
compared with the number of cases; b)
patients presented a great diversity of clinical
manifestations of the disease; and c) a differ-
ent degree of morbidity was observed among
members of the same household who shared
meals. These aspects suggest that a metabolic
factor is the basis of these differences.
Genetic, immunologic, or metabolic factors
are frequently involved in the pathogenesis
of this type of disease (53).
Alternatively, the present results may
point to a metabolic characteristic of TOS
survivors with regard to TOS deceased
patients. Thus, a particular metabolic profile
of the survivors of TOS may have acted as a
prognostic factor more than as a risk factor. It
was impossible to confirm this hypothesis,
which would have substantially reinforced our
results, because of the absence of frozen tissue
samples at the beginning of the study. We
attempted to extract DNA from tissue blocks
fixed in formalin and were unsuccessful due
to the quality of the available samples at the
time of the study.
One of the best designs for investigating
potential risk factors in an outbreak is a
case–control study (54). With regard to the
control group, the selection of “the best
friends of the case” has been used successfully
(55). Moreover, we selected two different
control groups, siblings and friends, to test
the hypothesis under different scenarios. Both
controls groups were used only on the basis of
the absence of TOS disease, but not as repre-
sentative of a population (no sampling was
performed). Nevertheless, CYP2D6 and
NAT2 allele frequencies found in friends
were similar to those reported in other stud-
ies with larger Spanish populations (56–58).
To avoid confounding factors, we decided to
choose matched controls to adjust for expo-
sure to oil consumption and other habits.
However, one of the drawbacks of this kind
of design is the possibility of overmatching
(55,59). In our opinion, this may help to
explain the absence of significant NAT2
results in cases/siblings comparison. We
assumed that siblings and cases had experi-
enced the same exposure, although slight dif-
ferences in the amount of oil ingested could
have influenced results. In contrast, we were
not able to check whether the group of
friends actually were nonexposed. Chemical
analysis of the oils collected from the epi-
demic showed that more toxic oil was sold
than was consumed by the families with cases
(60). Thus, we can assume that unaffected
subjects and cases from the same population
area had the same probability of being
exposed. 
It is impossible to recognize any individ-
ual biomarker before analyses are performed
unless the marker and the case selection
methods are associated. Being related to a spe-
cific group of victims or being a friend of a
case cannot justify a selection bias for this spe-
cific metabolic profile. Thus, the pharmacoge-
netic differences observed among these groups
could only be explained by a true risk factor.
It was not feasible to sex-match the group of
siblings. Similarly, we also decided not to pair
the friends group by sex; in fact, none of the
genetic factors under study are sex-linked.
Thus, the presence of defective alleles in
NAT2 and female cases in the final logistic
regression models cannot be justified by inter-
group sex differences. The overrepresentation
of females among cases was a feature of the
TOS epidemic (1,4,5). One explanation may
be a chance exposure related to household life
or an unidentified factor, perhaps epigenetic
modulation, associated with females.
An interesting point regarding xenobiotic
metabolism being a susceptibility factor is that
some pathways are tissue-specific markers. It
is feasible that the toxic agent(s) in the oil
would have followed two possible absorption
routes: directly to the lung through the tho-
racic duct or through the liver (3). Ultimate
toxic derivatives in the blood stream may
therefore be the result of these metabolic cir-
cuits. Moreover, experiments in rabbits and
mice known to have NAT polymorphisms,
revealed toxification symptoms depending on
the administration route (25,61). Anilides
and PAP esters identified in oil batches
should be considered arylamides and ary-
lamines, respectively. These two types of
chemical species differ in their basicity, nucle-
ophillicity, and ionization potential; as a con-
sequence, their chemical reactivity and
biotransformation may follow different path-
ways, resulting in several nucleophiles (62). In
addition, the fatty acid moiety in either
anilides or PAP esters confers a lipophilic
characteristic for their distribution. These
compounds share a chemical characteristic at
the aromatic moiety of being oxidized; this is
followed by complex conjugations, reduc-
tions,and/or hydrolysis (62), plausibly by
some of these enzyme pathways reported in
the present study. In particular, the contribu-
tion of CYP1A and NAT2 enzymes to the
metabolism of aniline-derived xenobiotics
such as acetanilide and phenacetin is well
known (63). In this respect, it is worth noting
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Table 4. Metabolic study variables among matching pairs of cases/siblings (n = 72) and cases/friends (n = 70).
Case/sibling pairs Case/friend pairs
Cases Siblings Cases Friends
Variable No. (%) No. (%) No. (%) No. (%)
Sex
Male 18 (25) 33 (45.8) 18 (25.7) 36 (51.4)
Female 54 (75) 39 (54.1) 52 (74.3) 34 (48.6)
CYP1A1
(C/D)a 11 (15.3) 7 (9.7) 11 (15.7) 4 (5.7)
(C/D + C/M,A)a 20 (27.8) 16 (22.2) 20 (28.6) 13 (18.6)
CYP2D6 (wt/m + m/m)b 34 (47.2) 29 (40.3) 33 (47.1) 28 (40)
NAT2 (wt/m + m/m)b 68 (94.4) 66 (91.6) 66 (94.3) 59 (84.3)
GSTM1 (GSTM1–)c 35 (48.6) 33 (45.8) 33 (47.1) 38 (54.3)
GSTT1 (GSTT1–)c 21 (29.1) 19 (26.4) 20 (28.6) 22 (31.4)
Distribution of functional metabolic categories derived from Figure 2 and Figure 3 were calculated in cases to compare
with the corresponding siblings or friends for statistical analyses. 
aNomenclature from Taioli et al. (45); bHeterozygous and homozygous nonfunctional haplotypes. cHomozygous deleted
gene.
Table 5. Conditional logistic regression analysis testing the association between metabolic variables and
cases of TOS.
Cases/Siblings Cases/Friends
Univariate Multivariate Univariate Multivariate
Variable OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Sex (female) 3.5 (1.4–8.7) 3.4 (1.3–8.6) 3.2 (1.5–7.2) 4.0 (1.7–9.8)
Age 1.1 (1.0–1.2) 1.1 (1.0–1.2) 0.9 (0.8–1.0) 0.9 (0.8–1.0)
CYP1A1 (C/D + C/M,A)a 1.6 (0.6–4.0) 2.0 (0.8–5.0)
CYP2D6 (wt/m + m/m)b 1.6 (0.7–3.9) 1.3 (0.6–2.5)
NAT2 (wt/m + m/m)b 2.0 (0.4–10.9) 1.4 (0.2–8.7) 3.3 (0.9–12.1) 6.96 (1.4–33.2)
GSTM1 (GSTM1–)c 1.2 (0.5–2.8) 0.7 (0.3–1.4)
GSTT1 (GST T1–)c 1.2 (0.5–3.2) 0.8 (0.4–1.9)
*Log LR = 10.9 *Log LR = 22.2
(p = 0.012) (p < 0.001 )
In each matching group, univariate analysis yielded the corresponding OR for each independent variable. The mathemati-
cal model built with all the variables included yielded the final OR after multivariate analysis. 
aNomenclature from Taioli et al. (45). bHeterozygous and homozygous nonfunctional haplotypes. cHomozygous deleted
gene. *Log of likelihood ratio tested as chi-square × degrees of freedom (n – 1) variables included in the final model.
that the molecular structure of fatty acid
anilides is similar to that of acetanilide and
that fatty acid anilides exert a specific inhibi-
tion on benzo(a)pyrene 3-hydroxylation, a
CYP1A1 marker (64). The fact that patients
ingested both anilides and PAP esters adds
more complexity to their biotransformation
and/or mutual interaction.
Although a theory of free radicals that
might involve glutathione conjugation was ini-
tially postulated (1,3), the present study clearly
shows no involvement of glutathione trans-
ferase polymorphisms. Methemoglobinemia
or tissue lesions such as those described by a
typical aniline–acetanilide intoxication (3)
have not been observed in TOS patients.
Thus, if aniline had been released from the
toxicant (i.e., by anilide/amide hydrolysis), it
would have been circumvented by conjugation
or other biotransformations. The potential
cotoxicity of anilides is intriguing. For exam-
ple, Berking et al. (65) recently reported a
lethal wasting disease in A/J mice treated
with oleylanilide The disease observed in A/J
mice, a slow acetylator strain, paralleled
some of the human TOS disease features,
whereas their homologous C57BL/6 strain
(a fast acetylator) had no symptoms. The
immunoresponse observed in these murine
strains shows a profile similar to that
described in TOS cases (33). The study of
Berking et al. (65) suggests that acetylation
may afford protection from reactive metabo-
lites derived from oleylanilide, leading to
toxicity. Using the same mouse strains,
ongoing studies in our laboratory have
shown that PAP oxidized metabolites at the
aniline moiety (66) and oxidized acetanilide
metabolites (67) were present in the animals’
urine after intraperitoneal administration of
14C-labeled PAP or oleylanilide. 
Genetic polymorphisms and epidemio-
logical tools such as those used in this study
might be useful in the examination of suscep-
tibility factors in other diseases caused by toxi-
cants. As far as TOS is concerned, the
consideration of altered phase II metabolic
pathways could be an important issue in
obtaining an animal model that permits more
in-depth analysis of the causal hypothesis. We
believe that the present results strongly sug-
gest the presence of a metabolic factor in the
presentation of the disease. Further studies
should be designed to confirm these findings.
One of our greatest future interests is to clar-
ify whether NAT2 mutations in TOS cases
are associated with particular symptoms or
sequelae, such as autoimmune disorders,
because impaired acetylation has been associ-
ated with skin disorders produced after chem-
ical exposure (68–71). Our laboratory is
currently investigating metabolic and distrib-
ution pathways of TOS-implicated aniline
derivatives in an animal model. We hope to
determine how other unexpected enzymes
may contribute to TOS pathogenesis and
how genetic polymorphisms may explain why
people living in the same household had dif-
ferent degrees of morbidity. 
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